IP Library Granted Patent US 10,597,647
Granted Patent B2
US 10,597,647 · App. 14/317,143 · Granted Mar 24, 2020

Compositions and methods for identifying hydroxymethylcytosine in a DNA

Inventors: Zhenyu Zhu (Beverly, MA); Janine Borgaro (Beverly, MA); Aine Quimby (Newton, NH); Shengxi Guan (Stoneham, MA); Zhiyi Sun (Gloucester, MA)
Assignee: New England Biolabs, Inc.
C12N9/22C12Q1/683
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,597,647
App. No.
14/317,143
Granted
Mar 24, 2020
Kind
B2
Abstract

Provided herein in some embodiments is a non-naturally occurring variant of a wild type restriction enzyme defined by SEQ ID NO: 20, wherein the variant has at least a 2 fold increase in cleavage at 5-β glucosylhydroxymethylcytosine (5βghmC) compared with methylcytosine relative to the wild type enzyme. Methods for examining hydroxymethylation of a DNA sample using the variant enzyme are also provided.

Claims (19)

1. A non-naturally occurring variant having at least 90% sequence identity to the corresponding wild type restriction enzyme in a family of related restriction endonucleases characterized by a consensus sequence of SEQ ID NO:21, wherein the variant has a mutation at one or more positions selected from positions corresponding to V72, T152 and R282 in SEQ ID NO: 11, and wherein the variant has at least a 2 fold increase in cleavage at 5-β glucosylhydroxymethylcytosine (5βghmC) compared with 5 methyl C (5mC) relative to the wild type enzyme.

2. The variant of claim 1 , wherein the variant has an amino acid substitution at a position corresponding to R282 of SEQ ID NO:11.

3. The variant of claim 2 , wherein the position corresponding to R282 of SEQ ID NO:11 is substituted with any amino acid except for F, Y, I, and V.

4. The variant of claim 2 , wherein the position corresponding to R282 of SEQ ID NO:11 is substituted with K, T, Q, L, S, M, C, N, G or A.

5. The variant of claim 2 , wherein the position corresponding to R282 of SEQ ID NO:11 is substituted with a G or A.

6. A method, comprising:

reacting a variant restriction enzyme of claim 1 with a DNA comprising one or more nucleotides selected from the group consisting of 5-β glucosylhydroxymethylcytosine (5βghmC) and hydroxymethylcytosine (hmC), for cleaving the DNA.

7. The method of claim 6 , further comprising:

determining at least one of the location of and the amount of 5hmC or 5βghmC in the DNA.

8. The method of claim 6 , wherein the method further comprises:

reacting the DNA with β glucosyltransferase (βGT) prior to reacting the variant enzyme with the DNA, thereby converting any hmC in the DNA to 5 βghmC.

9. The method of claim 6 , further comprising:

sequencing the DNA to create a hydroxymethylome map of the DNA.

10. The method of claim 6 , wherein the DNA is part or all of a genome.

11. The method of claim 6 , wherein the method comprises determining the presence or absence of 5hmC or 5βghmC at a predetermined position in the DNA.

12. A method, comprising:

a. obtaining a library of non-naturally occurring variants having at least 90% sequence identity to the corresponding wild type restriction enzyme in a family of related restriction endonucleases characterized by a consensus sequence of SEQ ID NO:21, wherein the variant has a mutation at one or more positions selected from positions corresponding to V72, T152 and R282 in SEQ ID NO: 11, and wherein the variant has at least a 2 fold increase in cleavage at 5βghmC compared with 5mC relative to the wild type enzyme

b. assaying for cleavage specificity of the variant enzymes for 5βghmC and for 5mC; and

c. selecting a variant having at least 2 fold increase in selectivity for 5βghmC versus 5mC compared to the wild type restriction enzyme.

Assignments (3)
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Sep 27, 2023
From: NEW ENGLAND BIOLABS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 065044/0729 →
CONFIRMATORY LICENSE Recorded Oct 3, 2014
From: NEW ENGLAND BIOLABS, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 033889/0136 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2014
From: ZHU, ZHENYU; BORGARO, JANINE; QUIMBY, AINE; GUAN, SHENGXI; SUN, ZHIYI
To: NEW ENGLAND BIOLABS, INC.
Reel/Frame 033647/0459 →
Continuity (2)
Provisional Application 61840946 · Jun 28, 2013
Related Publication 20150004596A1 · Jan 1, 2015